Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
|Articles|August 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 8
- Volume 5
- Issue 8
Number of US HIV Infections Steady
BETHESDA, Md--The number of Americans infected with HIV is holding steady at about 650,000 to 900,000, according to CDC data. This may be because the number of new HIV infections each year is roughly equal to the annual number of AIDS-related deaths, the report said.
Advertisement
BETHESDA, Md--The number of Americans infected with HIV is holdingsteady at about 650,000 to 900,000, according to CDC data. Thismay be because the number of new HIV infections each year is roughlyequal to the annual number of AIDS-related deaths, the reportsaid.
Articles in this issue
about 30 years ago
Chemo Improves Pain Relief in Advanced Prostate Cancerabout 30 years ago
NCCR Urges Congress to Support Senate Bill for Cancer Researchabout 30 years ago
Researchers Propose New Treatment Guidelines for HIVabout 30 years ago
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Andersonabout 30 years ago
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samplesabout 30 years ago
New Thinking on HIV Progression Leads to New Strategiesabout 30 years ago
Hospitals Told Not to Capitate for 'Wrong' Reasonsabout 30 years ago
More Study Needed of Possible Carcinogenesis of Winter Gas Additiveabout 30 years ago
President Makes NCAB AppointmentsAdvertisement
Related to this article
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
3
Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM
4
Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer
5